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There was a time in the latter decades of the 20th century when infectious disease was thought of as having been 
conquered. Antibiotics and Vaccines were working their wonders leaving the disabilities of age to become the front-
runners in the disease theatre. This was a mistake.  Today we know of millions of children who die because they are 
not vaccinated or because we do not have the vaccines that can protect them against the infectious diseases prevalent 
in their neighborhoods. And this, despite the terrific and noble efforts of foundations and governments to provide 
vaccines to the children of developing countries. So what are the problems that are holding us back from really 
defeating infectious diseases? Let me list some of them:-_ 
 
Regulatory Hurdles 
Vaccine costs 
 We need universal vaccines protective against all serotypes and subtypes of disease causing organisms 
 Problems with vaccine cost-benefit analyses 
 Vaccine R&D is funded at a level of 10% of that which goes to research into therapies 
 There is a need to Professionalise the Vaccinologist 
 We need to make a more determined effort to derive vaccines to protect against antibiotic-resistant bacteria 
 We need to better understand the inflammatory state and the methods to control it 
 The achievement of higher levels of acceptability for being vaccinated 
 There is a need for Massive Open On-Line Courses (MOOC) in Vaccinology 
 
As readers will note, this is a massive undertaking as each of the topic areas above can be the subject for a major 
paper. I will however, confine myself to a few explicatory remarks on each topic to justify their inclusion in this list.  
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1. Regulatory Hurdles 
 
Having demonstrated in humans in Phases I & II the safety and efficacy of a putative vaccine the further 
investigation of safety in massive Phase III trials may be unnecessary. Rather a licence to manufacture and sell the 
vaccine should be granted at the end of Phase II (having demonstrated efficacy) and then in the post-licensure Phase 
IV enhanced measures of surveillance should be brought to bear while the vaccine is in use in the field. This will cut 
the cost of the development of the vaccine by many hundreds of millions of dollars and bring the vaccine into the 
marked many years ahead of previous practice. Both of these effects will lead to a major decrease in the cost of the 
vaccine as well as having the effect of actually having a longer time of patented protection to recoup the 
development costs and make a profit. 
 
2. Vaccine costs 
 
The actual costs of making the vaccine (the stuff in the bottle) are generally below $5 per dose. Yet the cost of a new 
vaccine in the field may be over $50 per dose (cf the Novartis vaccine protective against the Meningococcus b 
strain). Much of such costs reside in the testing regimen which seeks to ensure the safety of the vaccine – the 
extended and enhanced use of cell culture tests for such determinations would make for a less expensive vaccine. 
 
3. We need universal vaccines protective against all serotypes and subtypes of disease causing 
organisms 
 
We are close to achieving a universal vaccine for influenza. In 2005 it was shown that there were epitopes on 
Rhinoviruses (over 90 non-cross neutralizing subtypes) that allowed cross-neutralization by monoclonal antibodies 
(1) and recently it has been shown that the Human Immunodeficiency Virus can elicit broadly neutralizing 
antibodies  (2). We need to make such vaccines for pathogenic forms of Pneumococci, Streptococci, Gonorrhea, 
Malaria, Papilloma Virus, Rotavirus and many others. 
 
4. Problems with vaccine cost-benefit analyses 
 
Those in charge of making policies for the implementation of programs of vaccination often use cost-benefit 
analyses to determine or justify their decisions to vaccinate or not to vaccinate. At present and following procedures 
of the Centre for Disease Control (CDC) of the USA a 3% or a 6% discount rate is applied to the value of the 
vaccine in the years following vaccination. This is questionable as the case may be made that the value of being 
vaccinated to the individual and the society increases with time as the costs of health care provisions rise with 
inflation and the development of more expensive treatments. Such a value will decrease as antibody/cellular 
protection mechanism erode with time. But it may also be that as people age they become less susceptible to disease. 
 
5. Vaccine R&D is funded at a level of 10% of that which goes to research into therapies 
 
When it comes to financing research and development in the health care area, most governmental bodies apportion 
less than 10% of their funds to protective and preventive projects than to repairing the damaged goods by therapies 
on which some 90%+ of the funding is devoted. Why is this the case? There is a natural sympathy with a person in 
pain and a natural dread of being in pain oneself. It is profitable to treat disease as it often recurs and sick people are 
prepared to pay a high price for relief from the symptoms of disease. This is in contrast to applying to a well infant 
or person a material that evokes a mild stimulus that causes an effect that resembles the disease state without, 
generally, any debilitating manifestations of that disease state. Furthermore, sales of medicines would decline were 
disease in abeyance which is a disincentive to vaccine development by the Pharmaceutical Companies but it should 
be an incentive to National Health bodies to set up the institutes for the development of vaccines. In some circles 
there is a fear (NOT justified by the data) that vaccines are inherently unsafe which provides an excuse to underfund 
development of new vaccines using funds from the society. 
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6. There is a need to Professionalise the Vaccinologist 
 
To meet the fears of those who seek to deny vaccines to themselves, their families and society at large it is necessary 
for those engaged in producing and applying vaccines to acquire the status and attributes of a Professional. For this 
an individual must satisfy an expert body well respected in the vaccine area that they have the necessary 
competences to make and apply vaccines. Additionally they have to be accepted as a member of a Professional 
association such as the International Society for Vaccines (isv-online.org) and publically accept to be bound by the 
code of conduct of that professional association which affirms the commitment of the professional to “do no harm”. 
In this way we may make inroads and reverse the negativity to vaccines of those amongst us who assert that 
vaccinators perpetrate damaging practices. 
 
7. We need to make a more determined effort to derive vaccines to protect against antibiotic-resistant 
bacteria 
 
Typical of many recent newspaper and leader articles are headlines warning us of the emergence of more antibiotic-
resistant pathogenic organisms (3). Such articles do not mention the possibility that vaccines protective against such 
organisms can be sought and achieved. Bearing in mind the major achievements that have enabled Vaccinologists to 
be able to detect and make immunogenic epitopes and incorporate these molecules into mixtures containing 
powerful adjuvants and stabilizers, it is remiss not to pursue such an approach to dealing with those bacteria that 
have learned how to side-step the lethal effects of current antibiotics. The magnitude and urgency of this problem is 
such that it may be wise to establish one or more specialized research institutes each sponsored by the society at 
large (out or taxes or charitable contributions) to tackle this problem. A spin-off from the work of such institutes 
would be more effective universal vaccines and a general understanding of the way such vaccines may be achieved. 
 
8. We need to better understand the inflammatory state and the methods to control it 
 
 
So much of our well-being depends on the state of our bodies’ inflammatory system. Not only do we rely on this for 
protection and rejection of pathogenic microbes but it also affects coronary heart disease, our susceptibility to 
cancer, allergy, arthritic states, myopathies and joint problems. This connects to vaccines via the immune system 
which is stimulated by the vaccination process. One of the components of that process is the inflammatory system 
and the inflammasome. There is little doubt that we are still in the foot-hills when we review our knowledge of the 
components and mechanisms that operate via our immune systems. So, this too becomes a target that we may use to 
challenge our skills and concepts so we may eventually achieve a much higher level of control over what our body is 
and the way it works.  
 
9. The achievement of higher levels of acceptability for being vaccinated 
 
When vaccination rates go down, the infections that would have been prevented by those vaccines rise. This has 
been made clear for both Pertussis and Measles in the Developed World. Presently, in the USA legislators at the 
State level have been wrestling with wording that makes it harder but not impossible to opt out of mandated 
vaccinations required for school entry. Nevertheless, overall rates of vaccination are of the order of 95% and only 
1%-6% of parents seek exemptions for their children. There is, however, a vociferous and active minority of people 
who seek to persuade others not to be vaccinated or allow their children to be vaccinated. There are also those who 
think that being vaccinated is of little value as some members of the medical profession claim when pressed to 
accept a vaccination protective against the most recent strains of influenza. A response to this situation has to be 
based on open reporting of the effects and side effects of vaccines with an emphasis on the considerable financial, 
social and psychological benefits that accrue from being vaccinated. 
 
10. There is a need for Massive Open On-Line Courses (MOOC) in Vaccinology 
 
Some 25% of people in the world lived on less than $1.25/day in 2008 (World Bank Figures). The provision of 
education in the area of vaccines (manufacture and use) to the people living in such areas has to be a target for those 
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who wish to ameliorate this situation. One way of achieving this end is to provide this education via the internet. 
Information relayed by satellite to solar power driven computers and televisions can provide a minimal cost delivery 
of the materials needed to educate local health workers and officials. The educators may be drawn from the most 
respected schools of education in all aspects of the generation, production, testing and use of vaccines. The 
development of educational tools via this Massive Open On-Line Course system is an active area in the Developed 
World but once the various tools and techniques have been assembled it will become available all over the world 
with little increase in expenditure.   
 
************************************** 
 
The present issue of the Procedia contains many examples of the efforts of research and development personnel to 
meet the kinds of challenges I have presented above. 
 
In terms of meeting the need for making vaccines available to more people at less cost I have presented a paper 
which seeks to understand how we might better use the concept of “Fairness” as a tool to get more people 
vaccinated and improve health and well-being all round. Following this we have papers reporting progress in the 
area of influenza vaccines where the emphasis is on the augmentation of the immunogenicity of the raw 
immunogen. This theme of modification of the immune response is expounded in a plague vaccine while other 
bacterial vaccines are under development for tuberculosis and melioidosis (caused by Burkholderia pseudomallei or 
Pseudomonas pseudomallei). In the veterinary area a respiratory disease of foals that used to be caused by an 
organisms called Rhodococcus equi (now renamed as Prescottella equi) is attracting work to produce a protective 
vaccine while work on Leishmania vaccines for dogs continues to improve prophylaxis in this area. Vaccines that 
protect young people for cervical carcinoma or genital warts continue to be in demand. Novel approaches to 
protection that involve making antibodies to receptors that pathogenic organisms might use are being explored while 
improved methods to store and transport vaccines are reaching the stage of wider use and application. 
 
The editor of these Procedia hopes that by publishing these comments and papers the subject area of vaccines and 
vaccination will be progressed and that those who present posters at future Vaccine and ISV annual congresses will 
prepare themselves to send in their manuscripts to this online publication. 
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